Dexcom Raises 2026 Revenue Outlook to $5.18B–$5.25B as It Targets Nearly 50% U.S. G7 15 Day Conversion by Year-End

In depth

Dexcom has raised its revenue guidance for 2026 to a range of $5.18 billion to $5.25 billion, reflecting confidence in its business trajectory. The company's primary focus is on driving adoption of its G7 15 Day continuous glucose monitoring device in the U.S. market, with a goal of achieving nearly 50% conversion among its user base by the end of the year. This ambitious target underscores management's expectation of sustained demand and successful market penetration for its latest glucose monitoring technology.